Mersana Therapeutics, Inc. announced today that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. Eastern Time on July 25, 2025. The company's common stock is expected to begin trading on a split-adjusted basis when the markets open on July 28, 2025, under its existing ticker 'MRSN' with a new CUSIP number.
The primary goal of this reverse stock split is to increase the per-share market price of the company’s common stock. This action is intended to enable Mersana to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The reverse stock split was approved by the company’s stockholders at the Annual Meeting held on June 12, 2025, with the final ratio determined by the Board of Directors.
At the effective time, every 25 shares of issued and outstanding common stock will be automatically reclassified and combined into one share of common stock. This will reduce the number of outstanding shares from approximately 124.8 million to approximately 5.0 million shares. No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive a cash payment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.